Mslp And Perrigo Stock Report From Pennytobuck.com
MusclePharm Corporation (OTCBB:MSLP), has announced it will retain ICR
, Inc., as its investor relations consulting partner.
ICR, Inc. was founded in 1998, and is a leading financial communications consulting firm that provides unmatched counsel from vertically focused senior-level professionals.
ICR has set a new standard for financial communications with a business model driven by deep, capital-markets expertise provided by a team of former Wall Street professionals, including senior sell-side analysts, portfolio managers and investment bankers.
ICR represents many clients across many verticals, including some of the most recognized brands in the healthy living markets.
For further information on MSLP and it's announcment goto http://pennytobuck.com/?p=3592.
Also MSLP is set to announce an exclusive distribution contract with PSI Distribution, a leading supplement distributor in Australia and New Zealand.
This contract will be worth $2 million in annual sales, allowing MSLP to expand into the Australian market and continue to grow as an international brand.
Australia is home to the second-fastest sellout in UFC history, as more than 16,000 tickets were sold on the first day for UFC 110 in February and is the third largest pay per view country for UFC events.
For more on this exclusive agreement goto http://pennytobuck.com/?p=2907.
Perrigo Company (Nasdaq:PRGO) reported results for its fourth quarter and full year ended June 26, 2010.
Perrigo's Chairman and CEO Joseph C. Papa commented, "For the fourth straight year, we delivered year-over-year record sales, earnings and cash flow from operations. Despite significant challenges, from competition in our largest product to stronger regulatory oversight, we remained focused on execution and delivered results ahead of our own expectations. During the year, we made two business acquisitions that expanded our portfolio into adjacent categories and new geographical areas. We extended our product pipeline into ophthalmics. We also entered strategic partnerships for new products leveraging Perrigo's powerful sales, marketing and distribution capabilities. We are continuing along our strategic path in these challenging times to make quality healthcare more affordable to consumers around the globe."
Fiscal Year Results
Net sales for fiscal 2010 were $2.27 billion, an increase of 13% over fiscal 2009. The increase was driven largely by strong performance in the Consumer Healthcare and Rx segments. The growth included consolidated new product sales of approximately $125 million. Reported gross profit was $746 million, up 25%, and the reported gross margin was 32.9%, up from 29.7% last year. The gross margin improvement was driven primarily by new products. Reported operating margin increased 250 basis points to 14.8% and adjusted operating margin increased 360 basis points to 16.9%. Reported income from continuing operations was $224 million, an increase of 59%. Adjusted income from continuing operations was $263 million, or an increase of 50% from fiscal 2009.
For the full article of Perrigo Revenue Results goto http://finance.yahoo.com/news/Perrigo-Reports-Record-prnews-235920354.html?x=0&.v=1.
For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations.The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty five thousand dollars in cash and twenty five thousand dollars in free trading stock from a third party (Bishop Equity Partners) for (30) days of advertising for Muscle Pharm Corp. (MSLP.OB).
by: Bill Pennyman
Lessons from Montecitorio and Madama Creative Ways To Make Money Now On Your Long Term Stock Investments Senz And Hershey Stock Update From Pennytobuck.com Why and Where to buy your Ice Hockey Stick The Making And Demise Of The Perfect Recording/part 2 Folding Cots: Convenience And Durability Buy Structured Settlement And Get These Benefits Caring For And Preserving Your Pool Table Settlement Advances For The Slip And Fall Case Eqlb, Senz Stock Report From Pennytobuck.com Fundamental Mistakes With The Back Stance (kokutsu Dachi) In Shotokan Karate Titlekey: How To Create Your Ex Want You Back And Understanding How To Do It Pet ID Tags and Animal Tags